Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Shankar, Lalitha; Schöder, Heiko; Sharon, Elad; Wolchok, Jedd D.; Knopp, Michael V.; Wahl, Richard L.; Ellingson, Benjamin M.; Hall, Nathan C.; Yaffe, Martin J.; Towbin, Alexander J.; Farwell, Michael D.; Pryma, Daniel A.; Poussaint, Tina Young; Wright, Chadwick; Schwartz, Lawrence H.; Harisinghani, Mukesh G.; Mahmood, Umar; Wu, Anna M.; Leung, David; Vries, Elisabeth G.E. de; Tang, Ying; Beach, Gillian; Reeves, Steven A.

doi:10.1016/s1470-2045(22)00742-2

Cited by 11 publications

(5 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Teaching patients about the role of biomarkers in selecting an immunotherapy treatment for their unique clinical situation and for integrating biospecimens in clinical trials is key to accelerating progress in immunotherapy biomarker development. In addition, developing minimally invasive biomarker strategies (eg, liquid biopsy 40 ) and non-invasive imaging technologies (immuno-positron emission tomography and others 41 ) will make the routine use of biomarkers and biomarker research more acceptable to both patients and providers.…”

Section: An Update To the Challenges And Opportunities In Cancer Immu...mentioning

confidence: 99%

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Emens,

Romero,

Anderson

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.

show abstract

Section: An Update To the Challenges And Opportunities In Cancer Immu...mentioning

confidence: 99%

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Emens,

Romero,

Anderson

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Examples include 89 Zr-DFO-CD3, which aims to predict immune response to therapy with CTLA-4 checkpoint inhibitors [196] and 89 ZED88082A [197] or 18 F-GEH200521, which have been developed to image CD8 + T cells dynamics in the context of immune checkpoint inhibitor treatment (NCT05629689). There is a need for new imaging tools to guide immunotherapy clinical trials for oncology patients [198].…”

Section: Imaging Immune Cellsmentioning

confidence: 99%

Advances in PET/CT Imaging for Breast Cancer

Jong

Desperito

Feghali

et al. 2023

JCM

View full text Add to dashboard Cite

One out of eight women will be affected by breast cancer during her lifetime. Imaging plays a key role in breast cancer detection and management, providing physicians with information about tumor location, heterogeneity, and dissemination. In this review, we describe the latest advances in PET/CT imaging of breast cancer, including novel applications of 18F-FDG PET/CT and the development and testing of new agents for primary and metastatic breast tumor imaging and therapy. Ultimately, these radiopharmaceuticals may guide personalized approaches to optimize treatment based on the patient’s specific tumor profile, and may become a new standard of care. In addition, they may enhance the assessment of treatment efficacy and lead to improved outcomes for patients with a breast cancer diagnosis.

show abstract

“…Moreover, the development of innovative imaging techniques, including positron emission tomography (PET) imaging with radiolabeled immune checkpoint inhibitors and tracers targeting CD8, is ongoing to improve response assessment 12 . The most developed are analyses of CT and magnetic resonance to extract more features and study whether such a radiomics approach could enrich the information for response analyses.…”

mentioning

confidence: 99%

“…It was concluded that in advanced solid tumors, a reduction in circulating tumor DNA levels in response to immune checkpoint inhibitors is associated with substantial improvements in outcome. Circulating tumor DNA change is an early response biomarker that may allow for a reduced frequency of cross-sectional imaging in patients receiving immune checkpoint inhibitors 12 .…”

mentioning

confidence: 99%

Towards evidence-based response criteria for cancer immunotherapy

et al. 2023

View full text Add to dashboard Cite

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

show abstract

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Cited by 11 publications

References 69 publications

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Advances in PET/CT Imaging for Breast Cancer

Towards evidence-based response criteria for cancer immunotherapy

Contact Info

Product

Resources

About